hepatocellular carcinoma

Exelixis and Ipsen Announce Positive CHMP Opinion for Cabometyx in Previously Treated Hepatocellular Carcinoma
Exelixis and Ipsen Announce Positive CHMP Opinion for Cabometyx in Previously Treated Hepatocellular Carcinoma
CP WIre
Exelixis
Ipsen
Cabometyx
hepatocellular carcinoma
Flag link:
Exelixis and Ipsen Announce Positive CHMP Opinion for Cabometyx in Previously Treated Hepatocellular Carcinoma
Exelixis
Ipsen
Cabometyx
hepatocellular carcinoma
Flag link:
Eisai and Merck Announce China Approval of Lenvima for Treatment of Unresectable Hepatocellular Carcinoma
Eisai
Merck
Lenvima
liver cancer
hepatocellular carcinoma
Flag link:
European Commission Approves New First Line Treatment for Advanced or Unresectable Hepatocellular Carcinoma – First in a Decade
European Commission Approves New First Line Treatment for Advanced or Unresectable Hepatocellular Carcinoma – First in a Decade
CP WIre
Eisai
Merck
Lenvima
hepatocellular carcinoma
Europe
Flag link:
European Commission Approves New First Line Treatment for Advanced or Unresectable Hepatocellular Carcinoma – First in a Decade
Eisai
Merck
Lenvima
hepatocellular carcinoma
Flag link:
Eisai-Merck partnership picks up first-line Lenvima approval
Eisai-Merck partnership picks up first-line Lenvima approval
Biopharma Dive
FDA
Eisai
Merck
Lenvima
hepatocellular carcinoma
Flag link:
Bayer growth hope Stivarga boosts survival in liver cancer patients
Bayer growth hope Stivarga boosts survival in liver cancer patients
Fierce Pharma
Bayer
Stivarga
liver cancer
Nexavar
hepatocellular carcinoma
Flag link:
FDA Grants Fast Track Designation to Can-Fite's CF102 in the Treatment of Liver Cancer
FDA Grants Fast Track Designation to Can-Fite's CF102 in the Treatment of Liver Cancer
Yahoo
Can-Fite BioPharma
CF102
FDA
fast track
hepatocellular carcinoma
liver cancer
Flag link:
Isis/AstraZeneca Expand Antisense Technology Collaboration
Isis/AstraZeneca Expand Antisense Technology Collaboration
Yahoo/Zacks
AstraZeneca
Isis Pharmaceuticals
antisense
ISIS-STAT3Rx
hepatocellular carcinoma
prostate cancer
ISIS-ARRx
Flag link:
Taiho Pharmaceutical Announces Termination of Phase III Clinical Trial of the Angiogenesis Inhibitor TSU-68 (orantinib) in Patients with Hepatocellular Carcinoma
Taiho Pharmaceutical Announces Termination of Phase III Clinical Trial of the Angiogenesis Inhibitor TSU-68 (orantinib) in Patients with Hepatocellular Carcinoma
Pipeline Review
TSU-68
Taiho Pharmaceutical
hepatocellular carcinoma
Flag link:
Celsion Stock Blown Apart On Thermodox Phase III Data
Celsion Stock Blown Apart On Thermodox Phase III Data
Seeking Alpha
Celsion
ThermoDox
hepatocellular carcinoma
Flag link:
ArQule enrolls first patient in Phase 3 trial for carcinoma candidate tivantinib
ArQule enrolls first patient in Phase 3 trial for carcinoma candidate tivantinib
Yahoo/Fly on the Wall
Arqule
tivantinib
hepatocellular carcinoma
Flag link:
Cleveland BioLabs hepatocellular carcinoma drug granted orphan status by FDA
Cleveland BioLabs hepatocellular carcinoma drug granted orphan status by FDA
Yahoo/Fly the on Wall
orphan drugs
hepatocellular carcinoma
Cleveland BioLabs
Quinacrine
Flag link:
Exelixis Reports Positive Preliminary Phase 2 Cabozantinib Data in Patients with Hepatocellular Carcinoma
Exelixis Reports Positive Preliminary Phase 2 Cabozantinib Data in Patients with Hepatocellular Carcinoma
Yahoo/BusinessWire
Exelixis
cabozantinib
hepatocellular carcinoma
Flag link:
Celsion Completes Consultative Review Process With EMA for Phase III HEAT Study of ThermoDox(R) in Primary Liver Cancer
Celsion Completes Consultative Review Process With EMA for Phase III HEAT Study of ThermoDox(R) in Primary Liver Cancer
Celsion
EMA
ThermoDox
hepatocellular carcinoma
liver cancer
radio frequency ablation
Flag link:
Exelixis Presents Positive Data
Exelixis Presents Positive Data
Yahoo/Zacks
XL184
Bristol-Myers Squibb
glioblastoma
brain cancer
melanoma
non-small cell lung cancer
small cell lung cancer
hepatocellular carcinoma
pancreatic
gastric
prostate
ovarian
breast cancer
Flag link: